NCT00496223View on ClinicalTrials.gov

A Phase I/II Study of Sunitinib and Dacarbazine

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Melanoma
Interventions
DRUG

Sunitinib

Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.

DRUG

Dacarbazine

Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER